Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selnoflast in COPD safety and PK study
NL-OMON51550Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Selnoflast with Placebo (2 arms). Primary endpoints: Adverse events, Abnormal laboratory findings and 1 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
selnoflast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON51550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51550.